Kadmon Holdings (KDMN) Received its Third Buy in a Row

By Jason Carr

After Jefferies and Mizuho Securities gave Kadmon Holdings (NASDAQ: KDMN) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Mark Breidenbach maintained a Buy rating on Kadmon Holdings today and set a price target of $8.00. The company’s shares closed last Thursday at $4.65.

According to TipRanks.com, Breidenbach is a 5-star analyst with an average return of 18.7% and a 43.9% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Global Blood Therapeutics, and Arvinas Holding Company.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kadmon Holdings with a $14.25 average price target, implying a 211.1% upside from current levels. In a report released yesterday, Mizuho Securities also assigned a Buy rating to the stock with a $13.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.73 and a one-year low of $2.30. Currently, Kadmon Holdings has an average volume of 3.39M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. It focuses on the treatment of autoimmune, inflammatory, and fibrotic diseases. Its products include Ribasphere, RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine. The company was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.